- cafead Jan 23, 2024 at 10:52: AM
via The next wave of gene editing advances will likely center not only on efficacy but on the diversity of where the therapies can be delivered, and Genentech is signing a new deal to keep up with the competition.
The Roche unit is paying $15 million and offering $629 million in biobucks to use GenEdit’s polymer nanoparticle-based platform to develop gene therapies for autoimmune diseases.
article source
The Roche unit is paying $15 million and offering $629 million in biobucks to use GenEdit’s polymer nanoparticle-based platform to develop gene therapies for autoimmune diseases.
article source